RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-17.9%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$4.58B
AUM Growth
+$4.58B
(-19%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
5.84%
Top 10 Holdings %
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$153M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$68.6M |
| 3 |
AN2 Therapeutics
ANTX
|
$55.3M |
| 4 |
Natera
NTRA
|
$53.3M |
| 5 |
Vera Therapeutics
VERA
|
$46.2M |
Top Sells
| 1 |
Novavax
NVAX
|
$103M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
$61.3M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$54.2M |
| 4 |
C4 Therapeutics
CCCC
|
$44.4M |
| 5 |
TG Therapeutics
TGTX
|
$42M |
Sector Composition
| 1 | Healthcare | 97.97% |
| 2 | Financials | 0.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Invivyd
IVVD
$204M
| – | – |
-4,995,807
| Closed | -$36.3M |
|
102
Nautilus Biotechnolgy
NAUT
$85.9M
| – | – |
-2,436,430
| Closed | -$12.6M |
|
|
103
Phathom Pharmaceuticals
PHAT
$864M
| – | – |
-3,115,008
| Closed | -$61.3M |
|
104
ARS Pharmaceuticals
SPRY
$1.15B
| – | – |
-1,742,186
| Closed | -$11.6M |
|
|
105
TG Therapeutics
TGTX
$4.65B
| – | – |
-2,210,145
| Closed | -$42M |
|
|
SYRS
106
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-900,000
| Closed | -$2.93M |
|
|
ZGNX
107
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-3,333,700
| Closed | -$54.2M |
|